Prosp Male BC

BOOG 2013-02

General Information

BOOG number

BOOG 2013-02

Nickname

Prosp Male BC

Status

Date: 07/12/2017

Participating parties / group

EORTC

Other study number

EORTC 10085

Full title

Male Breast Cancer: prospective into perspective

Indication

Subindication

Not applicable

Target sample size

270

Actual accrual

270
Date: 01/02/2018

Estimated study completion date

31/12/2017

Contact

Sponsor

BOOG Study Center

Principal Investigator(s)

C.P. Schröder, J.W.M. Martens, C.J. van Asperen

Study manager

A.E. van Leeuwen-Stok

Monitoring

Not applicable

Funding

Funding by Pink Ribbon

Other

Submitted to METC Groningen dd 19-8-2013 (2013/291) and judged being not applicable to WMO registration

Design

This nationwide study is a multicentre, prospective, observational and non-interventional study.

Objectives

The main objective is to initiate a nationwide, multicenter prospective registry of all male BC patients in order to give insight in the present-day treatment, outcome, side effects and gender related QoL aiming at implementation of this knowledge into treatment guidelines for male BC patients.

Secondary objectives are to evaluate the feasibility of a phase III prospective randomized clinical trial (focusing on specific psychosocial support and life style issues) by analyzing the recruitment of Male BC patients in the Netherlands in this study, to analyze blood and tumor tissue samples in relation to recently developed targeted therapies and treatment strategies aiming at personalized medicine and, finally, to use this registry for comparison with data from female BC patients (in a separate study).

Endpoints

In this observational study, main study parameters will focus on clinical outcomes (survival, progression free survival, time to locoregional relapse, time to distant relapse, time to second primary), patient and disease characteristics, QoL and patterns of treatment offered to these patients.

Eligibility Criteria

  • gender: male
  • diagnosis: primary invasive breast cancer (all stages of the disease)
  • age: over 18 years old at moment of diagnosis
  • mental competence and understanding of the Dutch language are required

Regulatory Information

CCMO approval

Yes
Amendments:
No

EudraCT number

Not applicable

Downloads

Inloggen